<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Genovese, Mark C.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy Maintained When Transitioning Directly from TNF Inhibitor to Tofacitinib in RA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with rheumatoid arthritis (RA) who transition directly from adalimumab to tofacitinib maintained a clinical response. This article presents results from the open-label extension Oral Rheumatoid Arthritis Phase 3 Trials Sequel study [ORAL; NCT00413699] of the randomized, double-blind, placebo-controlled ORAL Standard study in which the two treatments were compared in patients with active RA [NCT00853385].</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>